Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Assets (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Current Assets for 14 consecutive years, with $238.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 13.9% year-over-year to $238.1 million, compared with a TTM value of $238.1 million through Dec 2025, up 13.9%, and an annual FY2025 reading of $238.1 million, up 13.9% over the prior year.
  • Current Assets was $238.1 million for Q4 2025 at Heron Therapeutics, up from $229.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $366.8 million in Q2 2021 and bottomed at $165.3 million in Q2 2023.
  • Average Current Assets over 5 years is $222.7 million, with a median of $210.0 million recorded in 2024.
  • The sharpest move saw Current Assets plummeted 47.06% in 2022, then increased 17.53% in 2025.
  • Year by year, Current Assets stood at $254.4 million in 2021, then dropped by 19.25% to $205.4 million in 2022, then fell by 8.11% to $188.8 million in 2023, then grew by 10.72% to $209.0 million in 2024, then rose by 13.9% to $238.1 million in 2025.
  • Business Quant data shows Current Assets for HRTX at $238.1 million in Q4 2025, $229.4 million in Q3 2025, and $210.9 million in Q2 2025.